---
title: "Johnson Pharmacare Ltd (532154) — Share Price, Financials & Analysis"
symbol: "532154"
company: "Johnson Pharmacare Ltd"
canonical: "https://tapetide.com/stocks/532154"
isin: "INE560F01022"
nse_symbol: "JOHNSONPHARMACARELTD"
bse_code: "532154"
sector: "Commercial Services"
industry: "Diversified Services"
market_cap_cr: 25.85
generated_at: "2026-09-13T19:16:26.470Z"
---

# Johnson Pharmacare Ltd (532154)

Canonical page: https://tapetide.com/stocks/532154

## Company

- **NSE Symbol:** JOHNSONPHARMACARELTD
- **BSE Code:** 532154
- **ISIN:** INE560F01022
- **Sector:** Commercial Services
- **Industry:** Diversified Services
- **Macro Sector:** Services
- **Stock Type:** EQUITY
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** sunandshineworldwidetradelimited.in

## About

Johnson Pharmacare Limited, formerly Sun 
and Shine Worldwide Limited, is an investment-focused listed company with no demonstrated pharmaceutical operations.

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:45:44.427946Z.

- **Market Cap:** ₹25.85 Cr
- **Classification:** Microcap
- **P/E (reported):** -0.4
- **EPS (TTM):** ₹-1.03
- **EPS (reported):** ₹0
- **Book Value:** ₹0.01
- **Price to Book:** 57.5
- **Dividend Yield:** 0%
- **ROE:** -1.04%
- **ROCE:** -1.03%
- **Debt to Equity:** 0.02
- **Revenue (yearly):** ₹0 Cr
- **Net Income:** ₹-55.73 Cr
- **EBITDA:** ₹-57.05 Cr
- **52-Week High:** ₹0.8
- **52-Week Low:** ₹0.45
- **RSI (14):** 50.67

## Tapetide Score

- **Score:** 29 / 100
- **Score date:** 2026-09-04
- **Archetype:** Weak and Under Pressure
- **What it means:** Weak financials are the defining feature, and neither the valuation nor the trend reading is strong enough to offset them. Worth reading the risk flags and recent filings closely before anything else.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Falling
- **Percentile:** 1.4 (of 4473 scored stocks)
- **Confidence:** 77%
- **Data coverage:** 71%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 1.1 | 9.89% |
| momentum | 46.67 | 13.19% |
| ownership | 50 | 26.37% |
| quality | 21.62 | 24.18% |
| valuation | 17.4 | 26.37% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- Stock is trading at 57.5 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -29.6% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | — | -377.5% | — |
| ebitda margin growth | 100% | — | — | -100% |
| net income growth | 98.02% | — | — | — |
| revenue growth | -100% | — | — | -100% |
| roce | — | 212.12% | -54.42% | -0.68% |
| roe | — | 197.14% | -1.22% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 0 | 0 | 0.04 | 0 | 0.03 | 0.01 | 0.05 | 0 | 0.02 | 42.7 | 0.04 |
| Operating Profit | 0 | 0 | 0 | -0.04 | 0 | -0.03 | -0.01 | -0.05 | 0 | -0.02 | -42.7 | -0.04 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | -0.5 | 0 | 0 | 0 | -12.69 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.04 | 0.22 | 1.06 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | -0.04 | 0 | -0.03 | -0.51 | -0.05 | 0 | -0.06 | -55.61 | -1.1 |
| Tax % | — | — | — | 0 | — | 0 | 0 | 0 | — | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | -0.04 | 0 | -0.03 | -0.51 | -0.05 | 0 | -0.06 | -55.61 | -1.1 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | -0.01 | 0 | 0 | 0 | -1.01 | -0.02 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0 | 1 | 0 | 1 | 3 | 3 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 1 | 0 | 1 | 3 | 2 | 0 | 0 | 43 | 43 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -43 | -43 |
| OPM % | — | -1.1 | — | 0 | 4 | 9 | — | — | — | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 | -13 | -13 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | -1 | 0 | -1 | -56 | -57 |
| Tax % | 0 | 0 | 0 | — | 31 | -3 | 0 | 0 | 0 | — |
| Net Profit | 0 | 0 | 0 | 0 | 0 | -1 | 0 | -1 | -56 | -57 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | -0.02 | 0 | -0.01 | -1.01 | -1.03 |
| Dividend Payout % | 0 | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 50 | 50 | 50 | 50 | 50 | 55 | 55 | 55 | 55 | 55 |
| Reserves | 8 | 8 | 8 | 8 | 8 | 3 | 2 | 2 | 1 | -55 |
| Borrowings | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 1 | 21 |
| Other Liabilities | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| Total Liabilities | 59 | 60 | 60 | 59 | 59 | 60 | 60 | 60 | 58 | 22 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 54 | 54 | 53 | 52 | 52 | 54 | 46 | 46 | 42 | 20 |
| Other Assets | 5 | 6 | 7 | 7 | 7 | 6 | 14 | 14 | 16 | 2 |
| Total Assets | 59 | 60 | 60 | 59 | 59 | 60 | 60 | 60 | 58 | 22 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 11 | -1 | -1 | 0 | 0 | 5 | 0 | 0 | -2 | -57 |
| Cash from Investing Activity | -11 | 0 | 1 | 1 | 0 | -5 | -1 | 0 | 3 | 58 |
| Cash from Financing Activity | 0 | 1 | 0 | -1 | 0 | 0 | 1 | 0 | -1 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | 11 | -1 | -1 | 0 | 0 | 5 | 0 | 0 | -2 | -57 |
| CFO/OP | -8200 | 1417 | 9300 | -189 | — | 3800 | -200 | 25 | 764 | 134 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | — | — | 365 | — | 807 | 118 | 0 | — | — | — |
| Inventory Days | — | — | — | — | 0 | 0 | 0 | — | — | — |
| Cash Conversion Cycle | — | — | 365 | — | 807 | 118 | 0 | — | — | — |
| Working Capital Days | — | — | 1932 | — | 2267 | -9 | -141 | — | — | — |
| ROCE % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -105 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 85.56% | 85.56% | 85.56% | 85.56% | 85.56% | 85.56% | 85.56% | 85.56% | 85.56% | 85.56% | 85.56% | 85.56% |
| Others | 14.44% | 14.44% | 14.44% | 14.44% | 14.44% | 14.44% | 14.44% | 14.44% | 14.44% | 14.44% | 14.44% | 14.44% |
| No. of Shareholders | 116965 | 116971 | 116926 | 116901 | 117397 | 117101 | 117105 | 117098 | 117101 | 117101 | 117101 | 117101 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 1 / 7 / 11

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 0.47 | Sell |
| EMA (10) | 0.46 | Sell |
| SMA (20) | 0.46 | Sell |
| EMA (20) | 0.47 | Sell |
| SMA (50) | 0.47 | Sell |
| EMA (50) | 0.48 | Sell |
| SMA (100) | 0.51 | Sell |
| EMA (100) | 0.5 | Sell |
| SMA (200) | 0.53 | Sell |
| EMA (200) | 0.56 | Sell |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 45.57 | Neutral |
| MACD (12,26,9) | 0 | Sell |
| Stochastic (14,3,3) | 66.67 | Neutral |
| ADX (14) | 74.92 | Buy |
| Williams %R (14) | -50 | Neutral |
| ATR (14) | 0.01 | Neutral |
| ROC (12) | 0 | Neutral |
| Stoch RSI (14) | 27.66 | Neutral |
| UO (7,14,28) | 59.33 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=23e28a7e-e80f-4489-9e76-8b0cf7c92e84.pdf) |
| 2026-08-13 | [Board Meeting Outcome for Outcome Of Meeting Of Board Of Directors Held On Thursday 13Th August 2026 At Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=15a9eda7-2307-4cf0-ba0f-b9d555e5a24f.pdf) |
| 2026-08-13 | [Undertaking For Non- Applicability Of Regulation 32 Of SEBI (LODR) Regulations 2015 For The Quarter Ended On June 30Th 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=66160b1d-e2ae-4377-be9c-8d5b25baa41f.pdf) |
| 2026-08-11 | [Announcement under Regulation 30 (LODR)-Change in Registered Office Address](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b29eb9b0-cc9c-4926-9284-e0304069b700.pdf) |
| 2026-08-08 | [Board Meeting Intimation for Prior Intimation Of Board Meeting For Approval Of Un-Audited (Standalone) Financial Results For The Quarter Ended On 30Th June 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=df596611-83bb-43fd-bb21-f98a92a83a93.pdf) |
| 2026-07-13 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=44cc74a1-4edf-44cc-a376-f4034ebd9841.pdf) |
| 2026-06-26 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d93b2b6d-84f5-43f7-9993-d63af0644504.pdf) |
| 2026-06-12 | [Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4f37f341-cbd1-4709-ba52-e0eebb2debe8.pdf) |
| 2026-06-01 | [Outcome Of Meeting Of Board Of Directors Held On Wednesday 27Th May 2026 At Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ed818e4a-5a05-49dd-ad5b-a2e693a60d85.pdf) |
| 2026-05-30 | [Compliances-Reg.24(A)-Annual Secretarial Compliance](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=49a3833d-5617-43ac-a628-1d525d281c44.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-13 | [Submission Of Un-Audited Financial Results Of (JOHNSON PHARMACARE LTD) For The Quarter Ended On June 30Th 2026 And Along With Limited Review Report Thereon.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9ea09b6a-4714-4ef9-9d07-484aafd0a67b.pdf) |
| 2026-06-19 | [Submission Of Audited Financials Results Of Jhonson Pharmacare Ltd. For The Quarter And Year Ended On March 31St 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0d9f7042-116a-4a94-9e8c-9ace8f671ea7.pdf) |
| 2026-05-27 | [Submission Of Audited Financial Results Of (JOHNSON PHARMACARE LTD) For The Quarter And Financial Year Ended On March 31St 2026 Along With Audited Report Thereon](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=665a9173-fa0f-44fc-8226-21b5509339e3.pdf) |
| 2026-05-27 | [Submission Of Audited Financial Results Of (JOHNSON PHARMACARE LTD) For The Quarter And Financial Year Ended On March 31St 2026 Along With Audited Report Thereon](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c42664fb-e772-44b0-855c-b2fa3abbc40b.pdf) |
| 2026-02-14 | [Submission Of Unaudited (Standalone) Financial Results Of (Johnson Pharmacare Limited) For The Quarter Ended On 31St December 2025 Along With Limited Review Report Thereon.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3879d24c-e9b1-4980-9187-a22717884562.pdf) |
| 2025-11-14 | [Un-Audited Financial Results For The Quarter And Half Year Ended As On 30Th September 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2b5acef9-72f1-41ab-9de3-6c3dbda76674.pdf) |
| 2025-07-23 | [Regulations 30 33 And Other Applicable Provisions Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=689244df-753c-4699-a5b2-0165cf6b91bc.pdf) |
| 2025-05-23 | [Regulations 30 33 And Other Applicable Provisions Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e3e130f8-5b19-4b22-99bf-3be06fab0d84.pdf) |
| 2025-01-31 | [Pursuant To Second Proviso To Regulation 30(6) And Regulation 33 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 We Hereby Inform You That The Board Of Directors Of The](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=62226867-d38b-47bd-9315-b20df870f442.pdf) |
| 2024-11-13 | [Un-Audited Financial Result Quarter And Half Year Ended On 30Th September 2024 Pursuant To Regulation 33 Of The SEBI (LODR) Regulations, 2015.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=efc0b4d9-7ee8-42cb-9d5b-646b396d9085.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Feb - Audio recording of Kuantum Papers Q3 FY26 earnings concall held 09-Feb-2026 now available online. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 9 Feb - Audio recording of Kuantum Papers Q3 FY26 earnings concall held 09-Feb-2026 now available online.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/48742d86-a898-4213-ac82-d818baa9fd73.pdf) |
| 8 Feb - NEWSPAPER CLIPPINGS OF UNAUDITED FINANCIAL RESULTS | [Announcement under Regulation 30 (LODR)-Newspaper Publication 8 Feb - NEWSPAPER CLIPPINGS OF UNAUDITED FINANCIAL RESULTS](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3f5296bb-7312-498d-be39-6d1613f843e3.pdf) |
| 30 Apr - Johnson Pharmacare confirms it is not a Large Corporate for FY 2025-26 under SEBI debt rules. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - Johnson Pharmacare confirms it is not a Large Corporate for FY 2025-26 under SEBI debt rules.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/753a6453-f7bb-4c6e-b406-4f635c6e3c1f.pdf) |
| 30 Apr - Johnson Pharmacare confirms it is not a Large Corporate for FY 2025-26 under SEBI debt rules. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - Johnson Pharmacare confirms it is not a Large Corporate for FY 2025-26 under SEBI debt rules.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/753a6453-f7bb-4c6e-b406-4f635c6e3c1f.pdf) |
| 2d - Company confirms it is not a Large Corporate for year ended March 31, 2026. | [Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 2d - Company confirms it is not a Large Corporate for year ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/ff36d1aa-24e3-483a-a5f3-1cacd645bace.pdf) |
| 2d - Board approved unaudited Q3 (Dec 31, 2025) results: Q3 loss Rs6.40 lakh; nine-month loss Rs12.34 lakh, limited review. | [Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday, 14Th February, 2026 As Per Regulation 30 Of SEBI (LODR) Regulations, 2015. 2d - Board approved unaudited Q3 (Dec 31, 2025) results: Q3 loss Rs6.40 lakh; nine-month loss Rs12.34 lakh, limited review.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/328d72b8-0cce-4da0-9cc5-f30fb39e1c02.pdf) |
| 21 Mar - Trading window closed from 1 April 2026 until 48 hours after audited Q4 FY2026 results declaration. | [Closure of Trading Window 21 Mar - Trading window closed from 1 April 2026 until 48 hours after audited Q4 FY2026 results declaration.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c8265975-c7e5-4e42-9a96-674e5be43e51.pdf) |
| 17 Feb - Board appointed VRSK & Associates as statutory auditor and Parul Agrawal as independent director, effective 13 Feb 2026. | [Board Meeting Outcome for Revised Outcome Of Meeting Of Board Held On Friday, 13Th February, 2026 At Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015('SEBI LODR Regulation'). 17 Feb - Board appointed VRSK & Associates as statutory auditor and Parul Agrawal as independent director, effective 13 Feb 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/66e6e3b1-0c81-4ce0-a8d2-73fd274f879b.pdf) |
| 17 Feb - Appointed Ms Parul Agrawal (DIN 11268580) as Additional Independent Director effective 13 Feb 2026. | [Announcement under Regulation 30 (LODR)-Change in Management 17 Feb - Appointed Ms Parul Agrawal (DIN 11268580) as Additional Independent Director effective 13 Feb 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5206fef8-b05d-4ef8-a6a1-81bd5eaf5e46.pdf) |
| 17 Feb - Appointed M/s VRSK & Associates as statutory auditor effective 13 Feb 2026 until ensuing AGM. | [Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s 17 Feb - Appointed M/s VRSK & Associates as statutory auditor effective 13 Feb 2026 until ensuing AGM.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8041e051-358e-4b95-953f-cb247e9e91be.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2025 | [Concall - Sep 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9423dbef-d2b9-4e06-9c5e-5c746d884eda.pdf) |
| Sep 2020 | [Concall - Sep 2020](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b240bdb1-264d-4d76-9788-c72b896b86d5.pdf) |
| Oct 2022 | [Concall - Oct 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/45bef3d1-aa33-4c18-bdb2-e5e7a04127a7.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fd170846-af85-456c-b689-4315617c262d.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d47faa7e-b880-4394-8300-8001e34787a2.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/dd6a7a9d-57ba-4404-9a37-f1425d04b410.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5fc120f1-2895-4fe5-9209-a5185f19da00.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f08c0413-d542-44ab-b28c-7af6ebf8de9a.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8572e8c5-a5c3-4dc1-94ab-e7bcffbe35ea.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9ec1f5ab-6bf9-4231-baef-e9835551200b.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1e432a28-22ed-4d7d-b152-22366b29f88c.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/70cd9eb0-0529-4bd7-ac76-d505d93f8422.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/53d0b347-a014-4111-93de-424d07934382.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/558c9342-3b94-4648-9216-2537b25dee02.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3632e5bc-291f-49db-988d-2aff5d140fba.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8ebd4c97-e744-45c7-93b3-e27ed4294437.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/532937/73411532937.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/532154/76096532154.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/532937/70439532937.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/532154/70045532154.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:16:26.470Z.